Last checked at 28 Jun 2018 11:56
Shield Therapeutics plc
("Shield" or the "Company")
Result of 2018 Annual General Meeting
London, UK, 28 June 2018. Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company, with a focus on addressing iron deficiency, is pleased to announce that at its Annual General Meeting held on 27 June 2018, shareholders passed all of the ordinary and special resolutions. The full text of each resolution is contained in the Notice of AGM, which is available on the Company's website.
-Ends-
For further information please contact:
Shield Therapeutics plc | +44 (0)207 186 8500 |
Carl Sterritt, Chief Executive Officer Karl Keegan, Interim Chief Financial Officer | |
Nominated Adviser and Joint Broker Liberum Capital Limited Christopher Britton/Steve Pearce
Joint Broker Peel Hunt LLP James Steel/Christopher Golden | +44 (0)20 3100 2222
+ 44 (0)20 7418 8900 |
Financial PR Advisor Consilium Strategic Communications | +44 (0)203 709 5700
|
Mary-Jane Elliott/Matthew Neal
|
About Shield Therapeutics plc
Shield Therapeutics is a commercial stage pharmaceutical company, delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of all adults with iron deficiency with or without anaemia which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.